EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm
On 24 January 2025, EQL Pharma AB (publ) (the "Company") issued senior secured bonds of SEK 350 million (the "Bonds"). The Bonds have been admitted to trading on the Transfer Market segment of Nasdaq First North Bond Market since 25 February 2025. In accordance with the terms and conditions of the Bonds, the Company has today submitted an application for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm.
The first day of trading in the Bonds on the corporate bond list of Nasdaq Stockholm is expected to be on or around 19 November 2025. In connection therewith, the Bonds will cease to be traded on the Transfer Market segment of Nasdaq First North Bond Market.
On account of the application for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm, the Company has prepared a prospectus for the Bonds. The prospectus has today been approved by and registered with the Swedish Financial Supervisory Authority. The prospectus will be available at the Company's website, https://investor.eqlpharma.com/, and at the Swedish Financial Supervisory Authority's website, https://www.fi.se/en/.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
Bifogade filer